FindTrial
Sign In

niacin (+) laropiprant

DRUG7 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

DyslipidemiaHypercholesterolemiaHyperlipidemiaMixed DyslipidemiaMixed HyperlipidaemiaMixed HyperlipidemiaPrimary HypercholesterolaemiaPrimary Hypercholesterolemia

Phase 1

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
CompletedNCT01012219
Merck Sharp & Dohme LLCMixed Hyperlipidemia, Primary Hypercholesterolemia
Start: 2009-11-30End: 2010-04-30Updated: 2015-11-02

Phase 2

An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)
CompletedNCT00111891
Merck Sharp & Dohme LLCDyslipidemia
Start: 2005-06-30End: 2005-08-31Updated: 2017-02-17

Phase 3

Lipid Efficacy/Tolerability Study (0524A-020)
CompletedNCT00269204
Merck Sharp & Dohme LLCMixed Hyperlipidaemia, Primary Hypercholesterolaemia
Start: 2005-12-31End: 2006-12-31Updated: 2015-07-27
Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)
CompletedNCT00378833
Merck Sharp & Dohme LLCHypercholesterolemia, Hyperlipidemia
Start: 2006-07-31End: 2007-03-31Updated: 2017-02-16
Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)
CompletedNCT00479388
Merck Sharp & Dohme LLCMixed Dyslipidemia, Primary Hypercholesterolemia
Start: 2007-07-31End: 2008-10-31Updated: 2015-03-10
Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)
WithdrawnNCT00664287
Merck Sharp & Dohme LLCDyslipidemia
Start: 2008-09-30Updated: 2015-04-09

Unknown Phase

Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)
TerminatedNCT01228019
Merck Sharp & Dohme LLCHypercholesterolemia, Mixed Dyslipidemia
Start: 2010-12-31End: 2013-05-31Updated: 2015-04-21

Related Papers

Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
2012-06-0114 citations